Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats

被引:18
作者
Andersen, CU [1 ]
Mulvany, MJ [1 ]
Simonsen, U [1 ]
机构
[1] Aarhus Univ, Fac Hlth Sci, Dept Pharmacol, DK-8000 Aarhus, Denmark
关键词
molsidomine; sildenafil; pulmonary hypertension; acetylcholine; atrial natriuretic peptide; (chronic hypoxic rats);
D O I
10.1016/j.ejphar.2005.01.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study addressed whether combined treatment with a phosphodiesterase type 5 inhibitor, sildenafil, and a nitric oxide donor, molsidomine, prevents development of pulmonary hypertension in chronic hypoxic rats. Two weeks of hypoxia increased right ventricular systolic pressure, and right ventricular and lung weight. Treatment with either sildenafil (10 mg/kg/day) or molsidomine (15 mg/kg/day) in drinking water reduced right ventricular systolic pressure and weight, while lung weight was unchanged. Combining sildenafil and molsidomine did not have additional effects compared to molsidomine alone. The number of muscularized pulmonary arteries with diameters below 50 gm was increased in vehicle and sildenafil-treated, but not in molsidomine-treated hypoxic rats. Acetylcholine relaxation was blunted in arteries from vehicle and molsidomine-treated, but not in sildenafil-treated rats. In conclusion, both sildenafil and molsidomine blunts pulmonary hypertension and right ventricular hypertrophy in chronic hypoxic rats, but no synergistic effects were observed. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 36 条
[11]   Nitric oxide and molsidomine in the management of pulmonary hypertension in Takayasu's arteritis [J].
Lee, SD ;
Kim, DS ;
Shim, TS ;
Lim, CM ;
Koh, K ;
Kim, WS ;
Kim, WD .
CHEST, 2001, 119 (01) :302-307
[12]   Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension [J].
Lepore, JJ ;
Maroo, A ;
Pereira, NL ;
Ginns, LC ;
Dec, GW ;
Zapol, WM ;
Bloch, KD ;
Semigran, MJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (06) :677-+
[13]  
Lucas KA, 2000, PHARMACOL REV, V52, P375
[14]  
MacLean MR, 1997, J PHARMACOL EXP THER, V283, P619
[15]   Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension [J].
Mathew, R ;
Gloster, ES ;
Sundararajan, T ;
Thompson, CI ;
Zeballos, GA ;
Gewitz, MH .
JOURNAL OF APPLIED PHYSIOLOGY, 1997, 82 (05) :1493-1498
[16]   Nitric oxide donor drugs [J].
Megson, IL .
DRUGS OF THE FUTURE, 2000, 25 (07) :701-715
[17]   Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension - Comparison with inhaled nitric oxide [J].
Michelakis, E ;
Tymchak, W ;
Lien, D ;
Webster, L ;
Hashimoto, K ;
Archer, S .
CIRCULATION, 2002, 105 (20) :2398-2403
[18]   MECHANICAL-PROPERTIES OF VASCULAR SMOOTH-MUSCLE CELLS INSITU [J].
MULVANY, MJ ;
HALPERN, W .
NATURE, 1976, 260 (5552) :617-619
[19]   Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension [J].
Murray, F ;
MacLean, MR ;
Pyne, NJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (08) :1187-1194
[20]   Relaxation to authentic nitric oxide and SIN-1 in rat isolated mesenteric arteries: variable role for smooth muscle hyperpolarization [J].
Plane, F ;
Sampson, LJ ;
Smith, JJ ;
Garland, CJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (05) :665-672